Machine learning-based QSAR and molecular modeling of phytocompounds in Barleria buxifolia L. as a potential aldose reductase inhibitor

基于机器学习的定量构效关系(QSAR)和分子建模研究了巴氏刺槐(Barleria buxifolia L.)中的植物化合物作为潜在醛糖还原酶抑制剂的作用

阅读:1

Abstract

INTRODUCTION: The traditional medicinal plant Barleria buxifolia L is well-known for its pharmacological properties. This study aims to predict the binding affinity of bioactive compounds obtained from B. buxifolia towards significant molecular targets associated with diabetes mellitus. The polyol pathway enzyme aldose reductase is associated with diabetes, making it a possible therapeutic target. METHODS: By redocking the co-crystallised ligand sulindac sulfone into the aldose reductase binding site, the researchers proved the docking approach's reliability with a 0.117 Å root mean square deviation (RMSD). Virtual screening showed that 9-Carbomethoxy-6,11-dichloroxy-5-oxoxantho [3,2-g] tetralin (9CDOT) as a promising inhibitor, surpassing sulindac sulfone, which had a glide score of -9.95 kcal/mol and binding energy of -55.10 kcal/mol. RESULTS: The chosen molecule exhibited significant binding affinity through π-π interactions with Trp111 and Trp219, a stabilising hydrogen bond with Leu300, and hydrophobic contacts with Val297, Ala299, and Leu300. Halogen bonding connections were found with one chlorine facing Trp219, suggesting π-halogen interaction, and the other towards Leu300 and Leu301, indicating halogen-hydrophobic stabilisation. Synergistic interactions increase ligand target site affinity and specificity. The compound was non-hepatotoxic, non-neurotoxic, and non-cytotoxic, according to the toxicity prediction. Our investigation shows that 9CDOT, a phytocompound from B. buxifolia, strongly inhibits human aldose reductase. DISCUSSION: The molecule is considered to be one of B. buxifolia's active antidiabetic principles, making it a promising aldose reductase inhibitor lead candidate. Further verifying its potency, an AI-assisted PCA-PLS QSAR model also showed high predictive performance (R2 = 0.692), with 9CDOT showing a projected pIC(50) of 7.52 (IC(50) = 30 nM). To determine its therapeutic efficacy and investigate its potential as a lead candidate for the management of diabetes complications, more experimental validation is required.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。